4/6
08:02 am
adag
Adagene (ADAG) had its price target raised by Guggenheim from $9.00 to $10.00. They now have a "buy" rating on the stock.
High
Report
Adagene (ADAG) had its price target raised by Guggenheim from $9.00 to $10.00. They now have a "buy" rating on the stock.
4/2
08:09 pm
adag
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs [Yahoo! Finance]
Medium
Report
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs [Yahoo! Finance]
4/2
08:42 am
adag
Adagene announces pricing of $70M public offering of ADS [Seeking Alpha]
Medium
Report
Adagene announces pricing of $70M public offering of ADS [Seeking Alpha]
4/2
07:10 am
adag
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Medium
Report
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
4/2
07:01 am
adag
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
High
Report
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
4/2
07:00 am
adag
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
High
Report
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
4/2
02:25 am
adag
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
4/1
05:00 pm
adag
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
High
Report
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
3/21
01:31 am
adag
High
Report
3/17
05:14 pm
adag
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA [Yahoo! Finance]
Low
Report
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA [Yahoo! Finance]
3/17
04:35 pm
adag
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
Low
Report
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
3/9
09:11 pm
adag
Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon [Yahoo! Finance]
Medium
Report
Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon [Yahoo! Finance]
2/25
05:46 pm
adag
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk [Yahoo! Finance]
Medium
Report
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk [Yahoo! Finance]
2/17
10:06 am
adag
Adagene to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Adagene to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
2/17
09:27 am
adag
Adagene to Participate in Two Upcoming Investor Conferences
Medium
Report
Adagene to Participate in Two Upcoming Investor Conferences
2/12
05:31 pm
adag
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
High
Report
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
2/12
05:31 pm
adag
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
High
Report
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
2/11
04:00 am
adag
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
Medium
Report
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
2/2
10:00 am
adag
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
High
Report
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
1/23
08:00 am
adag
Adagene Provides Business Update and 2026 Objectives
High
Report
Adagene Provides Business Update and 2026 Objectives